Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib combined with etoposide after failure of second-line chemotherapy in small cell lung cancer
ChiCTR2000030474Phase 4Recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib and etoposide in small cell lung cancer (SCLC), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Progression-free survival. Started Mar 2020; status: recruiting.
02
Drugs
anlotinibetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2000030474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030474.